Daptomycin

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Staphylococcus Aureus

Conditions

Staphylococcus Aureus

Trial Timeline

May 1, 2006 → Sep 1, 2012

NCT ID

NCT00507247

About Daptomycin

Daptomycin is a phase 2 stage product being developed by Merck for Staphylococcus Aureus. The current trial status is completed. This product is registered under clinical trial identifier NCT00507247. Target conditions include Staphylococcus Aureus.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01025271	Pre-clinical	Terminated	May 1, 2010	May 1, 2011	Meningitis
NCT01019395	Phase 1	Completed	Jan 5, 2010	Mar 20, 2012	Gram Positive Bacterial Infection
NCT01012089	Pre-clinical	Completed	Nov 1, 2009	Apr 1, 2014	Chronic Kidney Disease
NCT00701636	Phase 3	Completed	Jul 1, 2008	Oct 1, 2010	Late Effects of Surgery
NCT00679835	Phase 1	Completed	Jun 3, 2008	Nov 20, 2008	Gram Positive Infection
NCT00490737	Phase 1	Completed	Aug 12, 2007	May 12, 2008	End-Stage Renal Disease
NCT00467272	Phase 2	Completed	Mar 1, 2007	Sep 1, 2012	Bloodstream Infection
NCT00663403	Approved	Completed	Feb 1, 2007	Apr 1, 2009	Critically Ill
NCT00507247	Phase 2	Completed	May 1, 2006	Sep 1, 2012	Staphylococcus Aureus
NCT00136292	Phase 1	Completed	Aug 24, 2005	Aug 9, 2006	Gram-positive Bacterial Infections
NCT00651131	Approved	Terminated	Jun 1, 2004	Mar 1, 2005	Wound Infections
NCT00055198	Phase 3	Terminated	Dec 19, 2002	Jan 26, 2004	Gram-Positive Bacterial Infections
NCT00093067	Phase 3	Completed	Mar 1, 2002	Feb 1, 2005	Bacterial Endocarditis
NCT00540072	Phase 3	Completed	Jul 30, 2001	Feb 27, 2002	Pneumonia, Bacterial
NCT00538694	Phase 3	Completed	Oct 31, 2000	Sep 30, 2001	Pneumonia, Bacterial

Competing Products

12 competing products in Staphylococcus Aureus

See all competitors

Product	Company	Stage	Hype Score
Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin	AbbVie	Phase 3	77
AZD7760	AstraZeneca	Phase 1/2	41
V710 + Placebo	Merck	Phase 2/3	65
Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO) + V710 Comparator: Placebo (PBO)	Merck	Phase 2	52
Imipenem/cilastatin	Pfizer	Approved	84
linezolid (Zyvox) + vancomycin	Pfizer	Approved	84
Linezolid + Vancomycin	Pfizer	Pre-clinical	22
Aurexis®	Bristol Myers Squibb	Phase 2	51
Aurexis® (tefibazumab)	Bristol Myers Squibb	Phase 2	51
blood samples + nasal swabs	Sanofi	Pre-clinical	22
Ceftobiprole medocaril + Daptomycin	Basilea Pharmaceutica	Phase 3	72
514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II	XBiotech	Phase 1/2	33

Other Products from Merck

DuleraApproved

ImipenemApproved

Mavenclad®Approved

raltegravir + PlaceboApproved

alendronate sodiumApproved